Search research articles
Contact Us
Filters
Showing results (11-20 of 42) with videos related to
Page
of 5
Sort By:
Journal of Comparative Effectiveness Research
|
February 25, 2021
Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer
Hope S Rugo, Anja Haltner, Lin Zhan, et al.
Molecular Biology of the Cell
|
June 8, 2004
Microtubule-dependent movement of late endocytic vesicles in vitro: requirements for Dynein and Kinesin
Eustratios Bananis, Sangeeta Nath, Kristie Gordon, et al.
Annals of the Rheumatic Diseases
|
August 22, 2014
How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?
Roy Fleischmann, Désirée van der Heijde, Andrew S Koenig, et al.
Journal of the American Academy of Dermatology
|
June 30, 2014
Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics
Philip J Mease, Dafna D Gladman, Philip Helliwell, et al.
Molecular Biology of the Cell
|
March 16, 2007
Kif5B and Kifc1 interact and are required for motility and fission of early endocytic vesicles in mouse liver
Sangeeta Nath, Eustratios Bananis, Souvik Sarkar, et al.
Journal of Breast Cancer
|
February 26, 2021
Palbociclib Plus Fulvestrant in Korean Patients from PALOMA-3 With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
Jee Hyun Kim, Seock Ah Im, Sung Hoon Sim, et al.
Annals of the Rheumatic Diseases
|
March 10, 2012
Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study
Paul Emery, Tore K Kvien, Bernard Combe, et al.
Clinical Rheumatology
|
April 16, 2018
Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials
Vibeke Strand, Eun Bong Lee, Yusuf Yazici, et al.
Annals of the Rheumatic Diseases
|
August 16, 2015
Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs
Christina Charles-Schoeman, Gerd Burmester, Peter Nash, et al.
Rheumatology and Therapy
|
February 9, 2018
Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis
Roy Fleischmann, Jürgen Wollenhaupt, Stanley Cohen, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 42) with videos related to
Sort By:
Page
of 5
Journal of Comparative Effectiveness Research
|
February 25, 2021
Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer
Hope S Rugo, Anja Haltner, Lin Zhan, et al.
Molecular Biology of the Cell
|
June 8, 2004
Microtubule-dependent movement of late endocytic vesicles in vitro: requirements for Dynein and Kinesin
Eustratios Bananis, Sangeeta Nath, Kristie Gordon, et al.
Annals of the Rheumatic Diseases
|
August 22, 2014
How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?
Roy Fleischmann, Désirée van der Heijde, Andrew S Koenig, et al.
Journal of the American Academy of Dermatology
|
June 30, 2014
Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics
Philip J Mease, Dafna D Gladman, Philip Helliwell, et al.
Molecular Biology of the Cell
|
March 16, 2007
Kif5B and Kifc1 interact and are required for motility and fission of early endocytic vesicles in mouse liver
Sangeeta Nath, Eustratios Bananis, Souvik Sarkar, et al.
Journal of Breast Cancer
|
February 26, 2021
Palbociclib Plus Fulvestrant in Korean Patients from PALOMA-3 With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
Jee Hyun Kim, Seock Ah Im, Sung Hoon Sim, et al.
Annals of the Rheumatic Diseases
|
March 10, 2012
Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study
Paul Emery, Tore K Kvien, Bernard Combe, et al.
Clinical Rheumatology
|
April 16, 2018
Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials
Vibeke Strand, Eun Bong Lee, Yusuf Yazici, et al.
Annals of the Rheumatic Diseases
|
August 16, 2015
Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs
Christina Charles-Schoeman, Gerd Burmester, Peter Nash, et al.
Rheumatology and Therapy
|
February 9, 2018
Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis
Roy Fleischmann, Jürgen Wollenhaupt, Stanley Cohen, et al.
Page
of 5